Mankind Pharma Ltd

Auditor resignation amid liquidation

• S.R. Batliboi & Co. LLP resigned as statutory auditors of Bharat Serums and Vaccines Limited.
• Resignation effective September 28, 2026, due to initiation of voluntary liquidation of BSV.
• Liquidation follows shareholders' September 7, 2026 resolution under IBC and VLP regulations.
• Auditors completed the year-end audit for March 31, 2026; report dated May 12, 2026.
• Regulatory requirement prohibits engagement of auditors during liquidation, prompting their immediate resignation.
• BSV is a material wholly owned subsidiary of Mankind Pharma Limited.

Mankind Pharma Limited — Trading window will be closed with effect from October 01, 2026 till 48 hours after the declaration of unaudited standalone and consolidated financial results of the Company for the quarter and half year ending on September 30, 2026.

Resolution summary

• Purpose: Special resolution to appoint Anish Vanraj Bafna as Non-Executive Independent Director for five years.
• Outcome: Passed; five-year term commencing Aug 10, 2026; total votes 396,204,784; 99.9627% in favour, 0.0373% against.

ESG rating update

• Niche99 ESG Ratings assigns Mankind Pharma 68.21 in Leader category for FY2025-26.
• The company did not engage Niche99; rating prepared independently.
• Niche99 is SEBI-registered Category II ESG rating provider.
• Disclosures available on the company's website.

Meeting Details

• 17 Sep 2026: Jefferies 5th India Forum, Gurgaon; One-on-One / Group Meeting; mode not specified.
• 18 Sep 2026: Health care Forum, Mumbai; One-on-One / Group Meeting; mode not specified.
• 21 Sep 2026: J.P. Morgan India Conference, Mumbai; One-on-One / Group Meeting; mode not specified.

Participants

• Company management/officials to participate in each conference.

Purpose

• Participation in investor conferences for general investor interaction.

Additional Notes

• Meetings subject to change; updated on company website.

BSVL liquidation update

• BSVL, a wholly owned subsidiary, approved voluntary liquidation at EGM Sep 7, 2026, subject to creditors' IBC approval.

Disposal of Broadway subsidiary

• 100% stake in Broadway Hospitality Services Private Limited transferred to AKRK Projects LLP and partners.
• Broadway ceases to be a wholly owned subsidiary with effect from August 31, 2026.

ESG Rating Update

• CRISIL ESG Ratings assigns Mankind Pharma ESG score of 64 in Strong category.
• Core ESG Rating improved to 71 from 60.
• Company states it did not engage CRISIL; report prepared independently using FY2026 disclosures and public data.
• Disclosure available on the Mankind Pharma website.
• No direct financial impact or metrics disclosed.

Deal overview

• Mankind Pharma signed an exclusive in-licensing and marketing agreement for Insulin Degludec and Degludec + Aspart in India.
• The deal strengthens the company's diabetes portfolio and injectables footprint in India.
• The licensor is Chongqing Chenan Biopharmaceutical Co., Ltd., China.
• The release highlights expansion of access to advanced therapies in India.